Products for Research Use Only

Peptide R54

CAT: 0804-HY-P11011Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P11011Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC50=20 nM) . Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma[1][2].
Product Name Alternative
Pep R54; CXCR4 antagonist peptide 19
UNSPSC
12352209
Target
CXCR
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Field of Research
Cancer
Smiles
O=C(N[C@@H](C)C(CN[C@H](CSSC(C)(C)[C@@H](C(O)=O)NCC([C@H](CC1=CNC=N1)NCC2=O)=O)C(N[C@@H](CCCNC(N)=N)C(CN[C@@H]2CC3=CC=C4C=CC=CC4=C3)=O)=O)=O)[C@H](CCCNC(N)=N)NC(C)=O
Molecular Formula
C48H71N15O9S2
Molecular Weight
1066.30
References & Citations
[1]D'Alterio C, et al. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1. J Exp Clin Cancer Res. 2019 Oct 28;38 (1) :432.|[2]Russo D, et al. The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells. PLoS One. 2024 Dec 19;19 (12) :e0314735.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
CXCR4

Popular Products